| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Evofem Biosciences, Inc.
13D
EVFM · 30048L302
|
10.0% |
8/4/2026
Event 6/30/2026
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.